Oat Milk for Laxation
Impact of Oat Milk Consumption on Gastrointestinal Transit and Defecation Frequency: A Controlled Intervention Trial in Adults
1 other identifier
interventional
100
0 countries
N/A
Brief Summary
This study intends to recruit 90-100 constipated participants aged 25-50 years, including an equal number of males and females, from the faculty and logistics staff of Capital Medical University. Participants will be randomly divided into an intervention group (55-60 individuals) and a control group (35-40 individuals). The intervention group will consume 250 mL of Mengniu Daily Fiber Oat Milk daily for 4 weeks, while the control group will not receive oat milk intervention. Both groups will maintain their original lifestyles, including diet, sleep, and exercise, throughout the study period. Baseline surveys, dietary surveys, blood and urine routine tests, blood biochemical indices, and intestinal flora detection will be conducted before and after the intervention. Defecation status will be recorded, and gastrointestinal symptoms will be assessed using a Gastrointestinal Symptom Rating Scale. Statistical analysis will be performed to determine the laxative efficacy of oat milk.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Dec 2025
Shorter than P25 for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 30, 2025
CompletedStudy Start
First participant enrolled
December 15, 2025
CompletedFirst Posted
Study publicly available on registry
December 24, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 15, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
February 15, 2026
CompletedDecember 24, 2025
December 1, 2025
1 month
November 30, 2025
December 11, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Changes in Intestinal Flora Composition Assessed by Metagenomic Sequencing
Fecal samples from a randomly selected subgroup (30 participants in the intervention group and 15 in the control group) will be collected before and after the intervention. Metagenomic sequencing will be used to evaluate changes in intestinal microbiota composition and functional gene pathways, including metabolism-, immunity-, and disease-related gene sets. This outcome explores potential mechanisms by which the intervention exerts laxative effects.
Collect feces and evaluate at baseline and at the fourth week.
Secondary Outcomes (1)
Changes in Gastrointestinal Symptoms Assessed by the Gastrointestinal Symptom Rating Scale
Participates will fill out the questionnaire at baseline, Week 2, and Week 4.
Study Arms (2)
Intervention Group
EXPERIMENTALControl Group
NO INTERVENTIONInterventions
The intervention group will consume 250 mL of Mengniu Daily Fiber Oat Milk daily for 28 consecutive days
Eligibility Criteria
You may qualify if:
- Clinical diagnosis of non-organic and habitual constipation;
- Reduced defecation frequency;
- Increased stool hardness;
- Fewer than 4 bowel movements per week;
You may not qualify if:
- Inability to take food orally or inability to comply with the required intake of the test product;
- Known allergy to oats or related products;
- Unclear primary gastrointestinal complaints;
- Physical weakness that prevents participation in the trial;
- History of surgery within the past 30 days that may cause constipation;
- Recent constipation caused by severe organic gastrointestinal lesions (e.g., colon cancer, severe enteritis, intestinal obstruction, inflammatory bowel disease);
- Constipation accompanied by significant abdominal pain;
- Acute gastrointestinal diseases within the past 30 days;
- Severe systemic diseases involving the cardiovascular, hepatic, renal, or hematopoietic systems;
- Ongoing treatment for comorbid conditions that may interfere with study participation;
- Recent use of substances related to the tested function that may influence outcome measurements.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Doctoral Student
Study Record Dates
First Submitted
November 30, 2025
First Posted
December 24, 2025
Study Start
December 15, 2025
Primary Completion
January 15, 2026
Study Completion
February 15, 2026
Last Updated
December 24, 2025
Record last verified: 2025-12
Data Sharing
- IPD Sharing
- Will not share